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The Emerging Role of HTLV-I/II and HIV-1 Among Intravenous
Drug Users in Detroit

Anthony F. Ognjan, MD,* Chris A. Lewandowski, MD,* Bradley T. Belian,
MSE, MA,* John Burczak, PhD,* Norman Markowitz, MD,* Helen Lee, PhD,*
and Louis D. Saravolatz, MD*

During 1987-1988, a seroprevalence study of the human immunodeficiency virus (HIV-1) and the
human T-cell lymphoma/leukemia virus (HTLV-l/II) was performed among Detroit intravenous
drug users unaffiliated wdh substance abuse programs. Seroprevalence data along with patient
demographic information were compared to a similar study peiformed in 1985-1986. In the earlier
study, 12 (12.5%) of 96 individuals tested posdive for HIV-1. Of lhe 74 available negative samples
retested in 1987-1988 for retroviruses, 7 (9.5%) tested posdive for HTLV-I/II. Thus, the overall
retroviral (HIV-1, HTLV-I/II)seropositive rate for 1985-1986 was 22%. In 1987-1988, 11 (15.7%)
of 70 individuals tested positive for HIV-1 and 7 (10%) tested positive for HTLV-I/II. Concomitant infection with both viruses was found in 2 (2.9%) of the 70 individuals. Thus, retrovirus seroprevalence in 1987-1988 was 22.9%. In 1987-1988, significant differences between the retroviralposiiive group and the retroviral-negative group consisted of intravenous drug use greater than 16
years (P = 0.059) for an odds ratio of3.80 (Cl 1.12-12.89) and sex with female prostitutes (P = 0.029)
foran odds ratio of 5.38 (Cl 1.38-20.95). (Henry Ford Hosp MedJ 1992;40:131-5)

O

ne in four individuals with the acquired immunodeficiency syndrome (AIDS) in the United States has used illicit
drugs (1). There are an estimated 1.1 million active intravenous
drug users (IVDUs) in the United States, but only about 15% receive substance abuse counseling (2). A total of 90% are heterosexual and 30% are women. Of the women, 90% are of childbearing age and 30% to 50% have engaged in sexual prostitution
(3). They represent the major source of perinatal transmission
of the human immunodeficiency virus (HIV-1) in the United
States (3-7). Seroprevalence of HIV-1 among IVDUs ranges
from less than 5% in most geographic areas of the United States
to 60% in New York City and surrounding areas (2).
The human T-cell lymphoma-Ieukemia virus (HTLV-I) is
the first human retrovirus to he described. Among the general
United States population, less than 1% are infected with HTLVI (8,9) which shares the same routes of transmission as HIV-1
(10-12). In I VDU populations, however, significantly higher
HTLV-I seroprevalence has been demonstrated. Serum specimens collected in 1971-1972 from 1,129 IVDUs from 43 .states
disclosed a seroprevalence of 6.3% (13). More recently, HTLVI seroprevalence among IVDUs of New York City ranged from
9% to 23% (14,15). Since HTLV-I cannot be readily distinguished from HTLV-II, we will refer to these two agents collectively herein as HTLV-I/II,
In the metropolitan Detroit area, the Detroit Police Department estimates that there are 30,000 to 40,000 active IVDUs
(16), Despite this large I VDU population, relatively few seroprevalence studies for HIV-1 have been conducted, and no sero-
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prevalence studies for HTLV-I/II exist. According to available
studies, HIV-1 seroprevalence ranged from 4.6% to 12.5% in
1985-1986 and from 7,8% to 13,8% in 1986-1987 (2,16),
This study was undertaken to examine the seroprevalence of
both HIV-1 and HTLV-I/It retroviruses in the IVDU population
of Detroit, to collect demographic and risk factor information
forthis population for 1987-1988, and to compare this information with a similar study performed in 1985-1986 (16),

Methods
Patient selection
This study attempted to enroll all patients with an identifiable
intravenous dmg use history who sought medical assistance in
either Henry Ford Hospital's Department of Emergency Medicine or Infectious Diseases Clinic between October 14, 1987,
and March 28, 1988, Henry Ford Hospital is a 923-bed acute
care facility located in the inner city of Detroit. The hospital
maintains an active Emergency Department that services the local area for general medical, trauma, and surgical problems. Patients were included in the study if they admitted to parenteral
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drug abuse within the preceding five years and provided informed consent before having their semm tested for HIV-1 and
HTLV-I/II. Informed consent was provided by alt patients. Each
was interviewed by a physician and completed an anonymous
questionnaire detailing individual demographics and dmg, sexual, social, and medical histories. Patients were excluded if they
had previously tested positive for HIV-1 or been diagnosed with
AIDS (Centers for Disease Control criteria).
Serologic screening
Collected semm was stored at -70° C along with semm collected in a similar epidemiologic study performed during 19851986. Serologic testing was performed in batches by the same
laboratory technicians to minimize laboratory variability in testing. Semm samples were tested for antibodies to HTLV-I/II and
HtV-1 by enzyme immunoassay (EIA) using purified viral lysate (Abbott Laboratories, North Chicago, IL). Repeatedly reactive samples by EIA were confirmed by Westem Blot. Those
EIA-positive samples that were indeterminate or negative by
Westem Blot methodology were further tested by radioimmunoprecipitation assay (RIPA) using 35^ methionine and cysteine labeled cell lysate (Abbott). Reactive samples by RIPA
were also considered positive.
Statistical analysis
Variables from the questionnaire were compared for seropositive and seronegative groups using Fisher's Exact test. Risk ratios and 95% confidence intervals (Cts) were also calculated.

Results
A total of 79 IVDUs were identified and enrolled. Complete
data (semm and completed questionnaire) were available for 70
individuals. Patients were excluded if their questionnaires were
incomplete or, most commonly, if they voluntarily withdrew
from the study after attempted phlebotomy.
A total of 74 (76%) of 96 samples collected in 1985-1986
were available for serologic study in 1987-1988. Of the original
96 specimens, 22 had been consumed while performing HIV-1
serology. The 12 HIV-1 positive specimens collected during
that study were among these 22 samples. None of the 74 remaining specimens retested positive for HtV-1 in 1987-1988 (Table
I) .
In 1985-1986, therefore, 12 (12.5%) of 96 individuals tested
positive for HIV-1. Of the 74 available samples retested in
1987-1988 for retrovimses, 7 (9.5%) of 74 tested positive for
HTLV-I/II. The minimum overall retroviral (HIV-1 4- HTLV-I/
II) seropositive rate for 1985-1986 is estimated to be 22% (Table 1).
In 1987-1988, 11 (15.7%) of 70 individuals tested positive
for HIV-1 and 7 (10%) of 70 samples tested positive for HTLVI/II. Concomitant infection with both viruses was reported in 2
(2.9%) of 70. The overall retrovims seroprevalence in 19871988 was 22.9%. tn 1987-1988, significant differences between
the retroviral-positive group and the retroviral-negative group
consisted of intravenous drug use greater than 16 years (P =
0.059) with an odds ratio of 3.80 (Ct 1.2-2.89) and sex with fe-
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male prostitutes (P = 0.029) for an odds ratio of 5.38 (CI 1.3820.95) (Table 2).
In 1987-1988, the average age was 40.6 years for the retrovims-positive group and 35,6 years for the retrovirus-negative
group. The HIV-1 seropositive group consisted of 11 subjects,
nine men and two women. The HTLV-I/II group numbered
seven, alt men. Black men predominated in this study, reflecting
the population served by the hospital's Emergency Department.
In 1987-1988, 51.5% of both retroviral-positive and retroviralnegative groups admitted past sharing of intravenous drug paraphemaUa (9 [60%] of 15 and 26 [49%] of 53, respectively). Sexual contact with other intravenous drug users did not differ between the retroviral-positive and the retroviral-negative groups
(56.3% versus 54.7%, P > 0.05). Additionally, six ofthe retroviral-positive group and 12 of the retroviral-negative group had
donated blood at some time in the past. Only two of the retroviral-positive group and one in the retroviral-negative group admitted to previous homosexual or bisexual contact. Other variables that were evaluated include previous illnesses, military
service, and imprisonment. These variables were not associated
with an increased risk of retroviral infection.
In the 1985 survey, 8 (67%) of 12 HIV-1 positive individuals
admitted sharing dmg paraphemalia, but only 40 (47.6%) of 84
of the retroviral-negative group admitted the same. Prostitute
contact occurred in 3 (25%) of 12 HIV-t positive individuals
and 13 (15.5%) of 84 HIV-1 negative individuals. Homosexual/
bisexual contacts were reported by one individual in the HIV-1
positive group and by three in the HIV-1 negative group. No
personal data were available for the HTLV-t/II positive individuals from the 1985-1986 survey.

Discussion
IVDUs constitute the second largest population at risk for
AIDS (1,2,17,18). A total of 25% of patients with AIDS in the
United States have a history of intravenous drug use. Most seroprevalence data among U.S. IVDUs have been obtained from
individuals seeking treatment at drug abuse treatment facilities
(2,18). Since only an estimated 15% of the 1.1 million IVDUs in
the U.S. are involved with treatment, existing HIV-1 seroprevalence data may not be representative of IVDUs as a whote (1820). Both of our 1985-1986 and 1987-1988 studies were conducted with active IVDUs not currentty involved in a detoxification or substance abuse clinic. These data therefore may represent a group more likely to retum to intravenous drug use upon
discharge from the hospital or emergency room and, for those
carrying the retrovims, to potentially disseminate it.
Detroit's IVDU population is on the upward slope of the epidemic curve of HIV-1 infection and AIDS, as has happened in
other metropolitan areas (21). tn New York City, HIV-1 seroprevalence of IVDUs increased from 12% in 1978 to greater
than 50% by 1984 (20,22). The seroprevalence among the
IVDUs of Detroit, which increased from 12.5% in 1985-1986 to
15.7% in 1987-1988, suggests that Detroit may be experiencing
a similar increase of which it is not aware because of the lack of
accurate, current estimates. It is possible that an anticipated increase in HlV-1 infection could be blunted if IVDUs were in-
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Table I
Seroprevalence of HTLV-I/II and HIV-1 in Detroit
Positive
Year
1985-1986
1987-1988

mv-i

HTLV-I

12 of 96 (12.5%)
11 of70(15,7%)

7 of 74 (9,5%)
7 of 70 (10.0%)

mv-i or

HTLV-I
and HIV-1

HTLV-I

*

— (22.9%)
16 of 70 (22.9%)

2 of 70 (2.9%)

*Twenly-two serum specimens from 1985-1986 were nol available for HTLV-I testing.

creasingly aware of the AIDS epidemic from educational programs, word of mouth, or the mass media (3,20,22-24). Awareness could lead to a reduction in exposure to retroviruses
through proper cleansing or nonreuse of drug paraphernalia,
safe sex practices, or dmg use modification (19,24-26).
Our study suggests a prevalence of HTLV-I/II in Detroit's
hospitalized IVDU population. Seroprevalence was 9.5% in
1985-1986 and 10% in 1987-1988. HTLV-I has been shown to
be endemic in southwestem Japan and further studies demonstrated increased seroprevalence of the virus in Africa, the Caribbean, South America, and the southeastem United States (2729). Among IVDUs in the United States, prevalence of HTLV-I
ranges from 6.3% (13) to 23% (15), compared to a prevalence of
0.028% in the general population (9). In our study, coinfection
with both HIV-1 and HTLV-I/II was found in 2.9% of IVDUs.
The clinical implications of simultaneous HTLV-I/II and
HIV-1 infection are unclear. Adult T-cell leukemia has been reported in a homosexual male from Trinidad (30), and a T8 lym-

phoproliferative disorder has been reported (31). More recently,
polymyositis (32) has been found in a patient infected with both
viruses. Further, it has been reported that human peripheral
blood lymphocytes infected with HIV-1 in vitro can be induced
to produce large quantities of HIV-1 after mitogenic stimulation
by HTLV-I virions (33). In theory, dually infected individuals
may produce greater quantities of HIV-1 that may result in more
severe (HIV-1-related) immunosuppression and enhanced facility to transmit the viruses or accelerate malignant transformation. Correspondingly, with the knowledge that both viruses are
transmitted in a similar fashion, it is noteworthy that HIV-1 infections were found in eight of 10 children in households of dually infected parents and in the two spouses of dually infected
men (34), However, no evidence of HTLV-I infection was
found among these individuals. The difference did not seem to
be related to lower numbers of HTLV-I-infected lymphocytes,
as all HTLV-I positive adults had a high proportion of HTLV-tinfected cells when compared to other HTLV-I-infected indi-

Table 2
Demographic Information Among Intravenous Drug Users of Detroit: 1987-1988
mv-i
N = 70
Age (years) (mean ± SD)
Male: Female
Black: White
Length IVDU (years) (mean ± SD)
IVDU > 16 years
Shared paraphemalia
Past Illness:
Endocarditis
Abscess
Pneumonia
Hepatitis B seroposirive
Sexual Behavior:
Sex with bisexual
Sex with IVDU
Sex with female prostitute
Other:
Military
Prison
Donated blood
Received blood

Odds
Rario

95%
Confidence
Interval

3.50
2.05

0.72-17.09
0.41-10.30

3.80
1.56

1.12-12.89*
0.49-4.99

9/53
17/53
8/53
4/48

2.22
2.12
2.56
1.00

0.62-7.97
0.68-6.60
0.70-9.36
0.10-9.86

2/14
9/16
6/14

1/46
29/53
6/49

2.50
1.06
5.38

0.20-31.00
0.35-3.28
I.38-20.95t

6/14
5/15
6/15
7/16

8/51
12/46
12/51
17/46

4.03
1/42
2.17
1.33

I.I0-I4.79t
0.40-4.99
0.64-7.33
0.42-4.21

HIV-1

HTLV-1

or
HTLV-1

Negative

11
39.7 ± 5
9:2
9:2
13.3±7
5/11
6/11

7
42.5 ± 5
7:0
7:0
15,1 ± 7
4/7
4/6

16
40,6 ± 5
14:2
14:2
13.3±7
7/16
9/15

54
35.6 ± 7
36:18
41:12
10.6 ± 6
9/53
26/53

2/11
6/11
3/11
1/S

4/7
3/7
3/7
0/5

5/16
8/16
5/16
1/12

0/9
6/11
3/9

2/5
4/7
3/6

4/10
3/10
2/10
4/11

.V6
3/7
4/6
4/7

*P = 0.059.
tP = 0.029.
tP = 0.068.
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viduats (34). When additional dually infected individuals are
identified and clinical cases develop, further studies should clarify the implications of coinfection with HTLV-I and HIV-1.
The sharing of dmg paraphemalia by IVDUs has been implicated in the spread of retroviruses (3,12,18,24,35). Approximately 50% of both the retroviral-positive and retroviral-negative groups in the present study admitted to sharing drug paraphernalia. By contrast, in 1985-1986, 75% of Deti-oit's HIV-1
positive IVDUs reported sharing paraphemalia, while only approximately 50% of the HIV-1 negative group admitted to this
practice. Clearly, the high rate of needle/syringe sharing among
all groups in both studies represents continued significant risk
for retroviral transmission among IVDUs. In addition, about
half of both retroviral-positive and retroviral-negative individuals report sex with other IVDUs. While sexual activity represents another avenue for potential retroviral spread among the
IVDU population, non-IVDU sexual partners among Detroit's
IVDUs are clearly also at risk.
A significantiy greater percentage of retroviral-positive individuals in 1987-1988 had contact with female prostitutes (48%
versus 12%, P = 0.0288), while prostitute contact was not associated with retroviral infection in 1985-1986. Although reasons
for this difference are unknown, the implications are that prostitutes can become an important reservoir for transmission not
only for their sexual partners but for their children as well.
Certain limitations exist in comparing the present study with
that of 1985-1986. Since the latter survey involved hospitalized
individuals, there may exist a selection bias for "sicker" IVDUs
who may represent a population more likely to be seropositive.
Therefore, it is possible that the apparent small increase in the
HIV-1 prevalence reported in the current study underestimates
the tme change that would occur if the groups were strictly comparable. Demographic information is not available for any of the
HTLV-I/II positive individuals in 1985-1986 nor is HTLV-I/II
seroprevalence available from the 22 HIV-1 positive individuals for that study. This information would be valuable in profiling more completely the retroviral-positive (HIV-1, HTLV-I/lt)
groups of 1985-1986.
Another selection bias introduced in the study was the exclusion of known HIV-positive or AIDS cases. This was consistent
with the effort to establish the prevalence of unknown HIV
cases. Because a community survey of IVDUs cannot be done
without significant danger to the researchers, the bias of studying only hospitalized patients was accepted in order to estimate
the prevalence of retroviral infection among IVDUs.
Containing and controlling communicable diseases is a desirable public health goal. Studies of retrovims among high-risk
groups in nonepidemic settings are necessary to plan for future
health care needs as well as to determine the resources required
for educational programs that may help halt further transmission.
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